CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering Majzner, R. G., Frank, M. J., Mount, C., Tousley, A., Kurtz, D. M., Sworder, B., Murphy, K. A., Manousopoulou, A., Kohler, K., Rotiroti, M., Spiegel, J. Y., Natkunam, Y., Younes, S. F., Sotillo, E., Vandon Duong, Macaulay, C., Good, Z., Xu, P., Labanieh, L., Wang, L. D., Alizadeh, A. A., Monje, M., Miklos, D. B., Mackall, C. L. AMER SOC HEMATOLOGY. 2020

View details for DOI 10.1182/blood-2020-139605

View details for Web of Science ID 000607547203139